These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 18443562)

  • 1. Hepatitis C associated cardiomyopathy: potential pathogenic mechanisms and clinical implications.
    Sanchez MJ; Bergasa NV
    Med Sci Monit; 2008 May; 14(5):RA55-63. PubMed ID: 18443562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [HLA and hepatitis C virus positive cardiomyopathy].
    Naruse TK; Inoko H
    Nihon Rinsho; 2000 Jan; 58(1):212-7. PubMed ID: 10885316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of hepatitis C virus in cardiomyopathies.
    Matsumori A
    Ernst Schering Res Found Workshop; 2006; (55):99-120. PubMed ID: 16329660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virology and pathogenesis of hepatitis C virus recurrence.
    Ramírez S; Pérez-Del-Pulgar S; Forns X
    Liver Transpl; 2008 Oct; 14 Suppl 2():S27-35. PubMed ID: 18825723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C virus infection and cardiomyopathies.
    Matsumori A
    Circ Res; 2005 Feb; 96(2):144-7. PubMed ID: 15692092
    [No Abstract]   [Full Text] [Related]  

  • 6. Hepatitis B virus and hepatitis C virus dual infection among patients with chronic liver disease.
    Saravanan S; Velu V; Nandakumar S; Madhavan V; Shanmugasundaram U; Murugavel KG; Balakrishnan P; Kumarasamy N; Solomon S; Thyagarajan SP
    J Microbiol Immunol Infect; 2009 Apr; 42(2):122-8. PubMed ID: 19597643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data.
    Negro F; Sanyal AJ
    Liver Int; 2009 Mar; 29 Suppl 2():26-37. PubMed ID: 19187070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy.
    Chehadeh W; Al-Nakib W
    J Med Virol; 2009 Apr; 81(4):610-8. PubMed ID: 19235842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular and molecular biology of HCV infection and hepatitis.
    Tang H; Grisé H
    Clin Sci (Lond); 2009 Jun; 117(2):49-65. PubMed ID: 19515018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular and molecular interactions in coinfection with hepatitis C virus and human immunodeficiency virus.
    Roe B; Hall WW
    Expert Rev Mol Med; 2008 Oct; 10():e30. PubMed ID: 18928579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Myocardial disease in viral infections. Myocarditis--cardiomyopathy].
    Brehm M
    Med Klin (Munich); 2006 Mar; 101 Suppl 1():36-9. PubMed ID: 16802516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antiviral therapy in viral heart disease].
    Pauschinger M; Noutsias M; Kühl U; Schultheiss HP
    Herz; 2004 Sep; 29(6):618-23. PubMed ID: 15912437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The transforming growth factor-beta high-producer genotype is associated with response to hepatitis C virus-specific therapy in HIV-positive patients with acute hepatitis C.
    Nattermann J; Vogel M; Nischalke HD; Danta M; Ahlenstiel G; Michalk M; Sauerbruch T; Rockstroh JK; Spengler U;
    AIDS; 2008 Jul; 22(11):1287-92. PubMed ID: 18580607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of chronic hepatitis C virus infection - Dutch national guidelines.
    de Bruijne J; Buster EH; Gelderblom HC; Brouwer JT; de Knegt RJ; van Erpecum KJ; Schalm SW; Bakker CM; Zaaijer HL; Janssen HL; Reesink HW;
    Neth J Med; 2008; 66(7):311-22. PubMed ID: 18663263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of steatosis and inflammation on liver fibrosis in chronic hepatitis C.
    Nieminen U; Arkkila PE; Kärkkäinen P; Färkkilä MA
    Liver Int; 2009 Feb; 29(2):153-8. PubMed ID: 18482270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.
    Maylin S; Martinot-Peignoux M; Moucari R; Boyer N; Ripault MP; Cazals-Hatem D; Giuily N; Castelnau C; Cardoso AC; Asselah T; Féray C; Nicolas-Chanoine MH; Bedossa P; Marcellin P
    Gastroenterology; 2008 Sep; 135(3):821-9. PubMed ID: 18593587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of chronic myocarditis in dilated cardiomyopathy referred for left ventriculoplasty: expression of tenascin C as a possible marker for inflammation.
    Tsukada B; Terasaki F; Shimomura H; Otsuka K; Otsuka K; Katashima T; Fujita S; Imanaka-Yoshida K; Yoshida T; Hiroe M; Kitaura Y
    Hum Pathol; 2009 Jul; 40(7):1015-22. PubMed ID: 19297005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Boceprevir, an NS3 protease inhibitor of HCV.
    Berman K; Kwo PY
    Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus and kidney disease.
    Martin P; Fabrizi F
    J Hepatol; 2008 Oct; 49(4):613-24. PubMed ID: 18662838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.